FDA Clears BD's C. Difficile Test as IVD | GenomeWeb

NEW YORK (GenomeWeb News) — Becton Dickinson unit BD Diagnostics said yesterday that it has received 510(k) clearance from the US Food and Drug Administration to sell its molecular diagnostic test to identify the bacterium Clostridium difficile in the US.

The company's GeneOhm Cdiff test is a rapid stool test to identify the bug's Toxin B gene, which is found in toxigenic C. difficile bacteria.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.